Clene Inc. 8K

Clene Inc. announced Q2 2026 results, highlighted its plan to file an NDA for CNM-Au8 in ALS under FDA’s accelerated approval pathway in early Q4 2026 supported by NfL biomarker data, and reported recent equity and debt transactions that extend its cash runway through late Q4 2026.

Clene Inc. reported its unaudited second quarter 2026 financial results and operating highlights, emphasizing that, following receipt of formal FDA meeting minutes in May 2026, it now plans to submit a New Drug Application in early Q4 2026 for CNM-Au8 for the treatment of ALS under the accelerated approval pathway, supported by new biomarker analyses showing that CNM-Au8-treated patients with declining or stable neurofilament light (NfL) levels experienced improved survival and function relative to controls. The company also disclosed that it closed a $7.0 million underwritten registered direct common stock offering to a single investor, amended and extended the maturity of its $10.0 million and $1.5 million senior secured convertible debt facilities to August 2027 while eliminating required payments prior to that date, and ended the quarter with $9.7 million of cash and cash equivalents, expecting this to fund operations through late Q4 2026. Financially, Clene generated modest product and royalty revenue, incurred flat R&D expenses and reduced G&A year over year, but reported a higher net loss of $13.4 million for the quarter, driven largely by non-cash increases in warrant and derivative liabilities and higher interest expense related to outstanding convertible debt.

Filing Facts

CIK

1822791

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-027837

Alert Tier

7